Showing all 2 results
Ticagrelor Tablets
FreeProduct Composition & Strength
We supply this product as a Precision-Blended Film-Coated Tablet, packed in highly secure, moisture-resistant Alu-Alu blister strips to ensure the absolute stability of the highly sensitive active pharmaceutical ingredient across all global climate zones.
Active Ingredient Strength Primary Clinical Use Ticagrelor INN/Ph.Eur. 90 mg Acute & Post-ACS: Standard twice-daily dose for the first 12 months following a heart attack or stent placement. Ticagrelor INN/Ph.Eur. 60 mg Extended Maintenance: Long-term prophylaxis for high-risk patients continuing therapy beyond the initial 12-month period. Excipients Mannitol / Dibasic Calcium Phosphate / Sodium Starch Glycolate / Hypromellose Diluent / Superdisintegrant / Film Coating (Engineered for immediate, highly predictable gastric dissolution) Trimetazidine Tablets
FreeProduct Composition & Strength
We supply this product as an advanced Modified-Release (MR) Film-Coated Tablet, packed in highly secure, moisture-resistant Alu-Alu blister strips to ensure the stability of both the active ingredient and the kinetic polymer matrix.
Active Ingredient Strength Primary Clinical Use Trimetazidine Dihydrochloride BP/Ph.Eur. 35 mg (Modified-Release) Global Standard: Twice-daily maintenance therapy for stable angina pectoris. Trimetazidine Dihydrochloride BP/Ph.Eur. 20 mg (Immediate-Release) Three-times-daily dosing for specialized dose titration or specific regional protocols. Excipients Hypromellose (HPMC) / Calcium Hydrogen Phosphate / Magnesium Stearate SR Polymer Matrix / Diluent / Lubricant (Engineered for strict 12-hour kinetic release)
